(Q46714958)

English

Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial

scientific article published on October 12, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Binghe Xu

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Zefei Jiang

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Zhimin Shao

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Jiayu Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Jifeng Feng

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Shuping Song

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Zhendong Chen

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Kangsheng Gu

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Shiying Yu

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Yiping Zhang

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Chuan Wang

11

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Fengchun Zhang

12

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Junlan Yang

13

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20938664

31 July 2024

publication date

12 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

full work available at URL

http://link.springer.com/content/pdf/10.1007/s00280-010-1483-x.pdf

Portable Document Format

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

http://link.springer.com/article/10.1007/s00280-010-1483-x/fulltext.html

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

http://link.springer.com/content/pdf/10.1007/s00280-010-1483-x

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

67

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

223-230

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

2

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

3

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

ICI 182,780, a new antioestrogen with clinical potential

5

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

6

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

7

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

8

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer

9

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

11

1 reference

10.1007/S00280-010-1483-X

https://api.crossref.org/works/10.1007/S00280-010-1483-X

31 July 2024

Identifiers

10.1007/S00280-010-1483-X

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/20938664

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46714958&oldid=2217326755"